Effects of intravenous theophylline on exercise-induced myocardial ischemia: II. A concentration-dependent phenomenon

Effect of theophylline on the warm-up phenomenon

This study examined whether the adenosine receptor antagonist theophylline prevents the warm-up phenomenon in patients with stable angina undergoing serial exercise tests. Our findings offer evidence that adenosine does not play a role in the warm-up phenomenon, and indirectly suggest that the warm-up phenomenon does not represent ischemic preconditioning in humans.

Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice

Theophylline, a drug that has been used for several decades, has several different actions at a cellular level, including inhibition of phosphodiesterase isoenzymes, antagonism of adenosine, enhancement of catecholamine secretion, and modulation of calcium fluxes. Recently, theophylline was found to have several immunomodulatory and anti-inflammatory properties, and thus interest in its use in patients with asthma has been renewed. The use of theophylline in the treatment of asthma and chronic obstructive pulmonary disease has diminished with the advent of new medications, but theophylline remains beneficial, especially in the patient with difficult refractory symptoms. In the future, theophylline may be used as treatment for bradyarrhythmias after cardiac transplantation, prophylactic medication to reduce the severity of nephropathy associated with intravenous administration of contrast material, therapy for breathing problems during sleep, and treatment for leukemias.

Safety of early intravenous dipyridamole technetium 99m sestamibi SPECT myocardial perfusion imaging after uncomplicated first myocardial infarction. Early Post MI IV Dipyridamole Study (EPIDS)

We assessed the safety of early (2 to 4 days) intravenous dipyridamole infusion in conjunction with technetium 99m sestamibi tomographic myocardial perfusion imaging in patients with first myocardial infarction (MI). Early risk stratification with myocardial perfusion imaging of patients after acute MI may be useful to identify patients who either require further evaluation or may be safely discharged. Because of minimal hemodynamic effects, intravenous dipyridamole may be a safe means of producing hyperemia for myocardial perfusion imaging. Stable patients with first acute MI who met entry criteria were randomized (3:1) to either intravenous dipyridamole infusion (0.56 mg/kg over a 4-minute period) 48 to 96 hours after onset of symptoms or a control (no test) group. Adverse cardiac events (unstable angina, recurrent MI, or cardiac death) were evaluated during and 24 hours after the dipyridamole infusion and during the corresponding 24 hours for the control group. Two hundred eighty-four patients received dipyridamole infusion a mean time of 3.3 +/- 0.7 days after MI. There were no adverse clinical events either during or immediately after the infusion. During the 24 hours after infusion, three patients had symptoms of unstable angina pectoris, one patient had a recurrent MI, and no patients died. The earliest event occurred 4.2 hours after the dipyridamole infusion. Three patients had unstable angina pectoris, whereas no patients had either recurrent MI or died in the control group. There were no statistically significant differences between the two groups. In a multicenter trial, dipyridamole infusion administered early after the first acute MI resulted in no increased evidence of cardiac events either immediately or 24 hours after the procedure compared with a control group. Therefore intravenous dipyridamole can be safely used as a pharmacologic vasodilator for myocardial perfusion imaging soon after uncomplicated MI.

Excessive myocardial contraction in vasovagal syncope demonstrated by echocardiography during head-up tilt test

The purpose of this study was to gain insight into the mechanism of vasovagal syncope and to test the efficacy of theophylline to prevent syncope. Twenty-six patients with vasovagal syncope underwent two-dimensional echocardiography and theophylline test during head-up tilt test. A standard parasternal short-axis view of echocardiography at the level of the papillary muscle was recorded to measure fraction shorting of the left ventricle, and left ventricular end-diastolic and end-systolic dimensions. Heart rate, blood pressure, and symptoms were recorded. There were three groups; Group 1: no syncope with and without isoproterenol (n = 5); Group 2: syncope only after the infusion of isoproterenol (n = 16); Group 3: syncope without isoproterenol (n = 5). Groups 2 and 3 proceeded to theophylline injection (250 mg). The study showed that the 80 degrees tilt induced an increase in heart rate of 6.6 +/- 4.0, 12.4 +/- 6.6, and 25.4 +/- 4.5 beats/min in Groups 1, 2, and 3, respectively (p < 0.05 in Groups 1 and 2, p < 0.05 in Groups 1 and 3). The addition of isoproterenol during posture change from supine to an 80 degrees tilt made the significant change of fractional shortening from 0.4 +/- 5% to 6 +/- 13% in Group 2 (p = 0.05), compared with no significant change in Group 1. There were no significant differences in left ventricular end-diastolic dimension and end-systolic dimension in each group between baseline and isoproterenol infusion during posture change. Vasovagal syncope was associated with vigorous myocardial contraction, rather than with contraction against an empty left ventricle. The acute loading of theophylline was not effective in preventing vasovagal syncope.

Effects of theophylline and dibutyryl-cAMP on adenosine receptors and heart rate in cultured cardiocytes

The effects of chronic exposure to the adenosine antagonist theophylline (Theo) and dibutyryl cyclic-AMP, a membrane-permeant derivative of the second messenger 3', 5'-cyclic-AMP (cAMP), on contractions and adenosine receptor levels in cultured cardiocytes were studied. Binding of the A1-adenosine receptor antagonist [3H]8-cyclopentyl-1,3-dipropylxanthine ([3H]CPX) was used to monitor the level of the receptors in intact cardiocytes. Both Theo and cAMP stimulated the rate of contraction and also increased the density of adenosine receptors. The Bmax value for [3H]CPX binding to intact cardiocytes was increased by 45-47% following 4 days of exposure to either 50 microM Theo or 100 microM cAMP. Scatchard analysis indicated that the affinity of the A1 receptors for [3H]CPX remained unchanged (Kd 0.1-0.2 nM). No significant differences were observed in protein content or in cell number. A linear correlation was achieved between the level of A1-adenosine receptors and heart rate at various Theo and dibutyryl-cAMP concentrations, although Theo was more efficient in elevation of the receptor density. Increases of 82, 78, 138 and 235% in A1 receptor density and increases of 63, 59, 66 and 150% in heart rate were obtained following 5 days of treatment with 1, 10, and 1000 microM of Theo, respectively. It is concluded that there is a linkage between the rate of cardiac contractions and the level of adenosine receptors. Thus, changes in the density of adenosine receptors may compensate for chronic drug-induced changes in cardiac contractile activity so as to restore conditions to the normal state.

Effects of short-term aminophylline administration on cardiac functional reserve in patients with syndrome X

OBJECTIVES

This study sought to evaluate the effect of adenosine receptor blockade by aminophylline on cardiac functional reserve in patients with syndrome X.

BACKGROUND

Aminophylline may have a potentially antiischemic effect through the inhibition of adenosine and, thus, the coronary steal phenomenon in patients with syndrome X.

METHODS

A single-blind, placebo-controlled study of an intravenous infusion of aminophylline (6 mg/kg body weight over 15 min) or placebo (20 ml of saline solution over 15 min) was performed during continuous radionuclide monitoring of left ventricular ejection fraction in 12 patients performing supine bicycle ergometric exercise.

RESULTS

Aminophylline increased exercise time (aminophylline 400 s vs. placebo 355 s, p < 0.01), decreased degree of ST segment depression (aminophylline 1.6 mm vs. placebo 2.4 mm, p < 0.01) and either abolished (seven patients) or diminished (five patients) chest pain during exercise. Aminophylline also increased left ventricular ejection fraction at rest (aminophylline 66.5% vs. placebo 62.3%, p < 0.05) but did not improve its deterioration at peak exercise (aminophylline 60.1% vs. placebo 56.6%, p = NS) or shorten the abnormally prolonged interval between the end of exercise and the overshoot (aminophylline 115 s vs. placebo 130 s, p = NS).

CONCLUSIONS

Aminophylline infusion increases ischemic threshold and prolongs exercise duration in patients with syndrome X. It is hypothesized that aminophylline acts by inhibiting the coronary steal phenomenon through adenosine receptor blockade. It does not improve the deterioration in left ventricular function at peak exercise or the delayed response in ejection fraction in the recovery period, presumably because the beneficial effects of aminophylline that result from the redistribution of coronary blood flow are limited.